Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Phase 2a in Persistent Moderate to Severe Eosinophilic Asthma
NCT01312961Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2011
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic asthma (EA) comparing Dupilumab 300 mg qw with Placebo (2 arms). Primary endpoint: Percentage of Participants With Asthma Exacerbation at 12 weeks. Started Mar 2011; status: completed.
02
Drugs
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT01312961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01312961.